• Mashup Score: 0

    Learn about causes, risk factors, and prevention for peripheral artery disease, or PAD, which is when the arteries are narrowed from plaque buildup, or atherosclerosis.

    Tweet Tweets with this article
    • September is #PeripheralArteryDisease Awareness Month. Knowledge is power! Inform patients about PAD and its risks, symptoms, and prevention. Together, we can foster healthier lives.❤️🩺 https://t.co/9ypLspy8on #MedTwitter #MedEd #PatientCare #PrimaryCare https://t.co/Mzoueqi9Ts

  • Mashup Score: 0

    According to a new scientific statement released by the American Heart Association, chronic exposure to contaminent metals found in household products, air, water, soil and food is linked to a greater risk of cardiovascular disease.

    Tweet Tweets with this article
    • A statement in @JAHA_AHA warned that chronic exposure to #HeavyMetals often found in household products, food, air, water & soil is linked to increased risk of #CoronaryArteryDisease, #stroke & #PeripheralArteryDisease. Dr. Herb Aronow explains more: https://t.co/E2WPUzAk3i

  • Mashup Score: 0

    Scientific papers/presentations related to novel PAD therapies: Lesion Modification with a Micro-Incision Vessel Preparation System Enhances Balloon-Based Drug Delivery in Complex Porcine Restenotic Lesions.Rami Tzafriri, Jay Budrewicz, Lynn Bailey, Peter Markham et al. Presented at LINC 2021, January 25, 2021. Balloon-based drug coating delivery to the artery wall is dictated by coating…

    Tweet Tweets with this article
    • RT @MedtechMatters: #EuroPCR. #CardioTwitter. #MedTwitter. #PeripheralArteryDisease. https://t.co/GMYbACTzVp https://t.co/9R1lw1z97d

  • Mashup Score: 1

    In this JAMA Author Interview, JAMA Interim Executive Editor Greg Curfman, MD, speaks with Mary M. McDermott, MD, professor of medicine at Northwestern University Feinberg School of Medicine, on current therapies for peripheral artery disease and a new clinical trial she directed on the use of telmisartan, an angiotensin receptor blocker, for patients with peripheral artery disease.

    Tweet Tweets with this article
    • JAMA Interim Executive Editor Greg Curfman, MD, speaks with Mary M. McDermott, MD, on current therapies for #PeripheralArteryDisease (PAD) and a new clinical trial she directed on the use of #telmisartan for patients with PAD. https://t.co/3aNHvhyOMO